Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
VYNE Stock Chart & Stats
$0.57
-$0.38(-8.88%)
At close: 4:00 PM EST
$0.57
-$0.38(-8.88%)
Day’s Range― - ―
52-Week Range$0.28 - $2.94
Previous CloseN/A
Volume117.27K
Average Volume (3M)2.75M
Market Cap
$18.84M
Enterprise Value-$9.91M
Total Cash (Recent Filing)$32.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Feb 26, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding33,286,423
10 Day Avg. Volume3,707,448
30 Day Avg. Volume2,746,500
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.74
Price to Sales (P/S)284.78
P/FCF Ratio-4.19
Enterprise Value/Market Cap-0.53
Enterprise Value/Revenue-18.92
Enterprise Value/Gross Profit-18.92
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$2.00Price Target Upside250.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financing / Cash RunwayPre-closing financing that provided approximately $200 million in cash proceeds for Yarrow to advance its pipeline strengthens the combined company's cash runway and supports planned program development.
Merger / Corporate TransactionDefinitive all-stock merger with Yarrow Bioscience and expected Nasdaq listing under ticker YARW could broaden market visibility and provide access to Yarrow's development resources.
Safety Profile / Clinical TolerabilityRepibresib exhibited a manageable safety profile in the trial, which may facilitate additional clinical exploration or combination strategies if efficacy opportunities emerge.
Bears Say
Clinical Trial FailureRepibresib missing the primary endpoint in the Phase 2b vitiligo trial undermines confidence in the drug's efficacy and could prompt a strategic reassessment of development plans.
Programmatic Risk / BET Inhibitor StrategySignificant clinical setbacks for VYNE's therapeutic candidates and increased perceived risk around the BET inhibitor approach may deter potential collaborators and pressure valuation.
Trial Termination / Funding UncertaintyDiscontinuing treatment in the extension phase and terminating the Phase 2b study creates uncertainty around future data readouts and could complicate efforts to secure additional funding.
VYNE Therapeutics News
VYNE FAQ
What was VYNE Therapeutics’s price range in the past 12 months?
VYNE Therapeutics lowest stock price was $0.28 and its highest was $2.94 in the past 12 months.
What is VYNE Therapeutics’s market cap?
VYNE Therapeutics’s market cap is $18.84M.
When is VYNE Therapeutics’s upcoming earnings report date?
VYNE Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 25 days.
How were VYNE Therapeutics’s earnings last quarter?
VYNE Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.173 by $0.003.
Is VYNE Therapeutics overvalued?
According to Wall Street analysts VYNE Therapeutics’s price is currently Undervalued.
Does VYNE Therapeutics pay dividends?
VYNE Therapeutics does not currently pay dividends.
What is VYNE Therapeutics’s EPS estimate?
VYNE Therapeutics’s EPS estimate is -0.23.
How many shares outstanding does VYNE Therapeutics have?
VYNE Therapeutics has 33,286,423 shares outstanding.
What happened to VYNE Therapeutics’s price movement after its last earnings report?
VYNE Therapeutics reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.173. Following the earnings report the stock price went up 4.748%.
Which hedge fund is a major shareholder of VYNE Therapeutics?
Currently, no hedge funds are holding shares in VYNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VYNE Therapeutics
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
VYNE Stock 12 Month Forecast
Average Price Target
$2.00
▲(250.88% Upside)
Technical Analysis
Ownership Overview
4.28% Insiders
1.77% Mutual Funds
0.08% Other Institutional Investors
93.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---